Emerging problems in the pharmacology of migraine: interactions between triptans and drugs for prophylaxis.
Patients suffering from migraine take drugs for many years in order either to relieve or to prevent recurrent migraine attacks. When two or more drugs are co-administered, there is always the possibility of drug-drug interaction. Interactions can be either kinetic or dynamic. The former are the most frequent ones. Mechanisms of kinetic interaction can be different, but the most common are represented by the induction or inhibition of enzymes of the cytochromes p450 (CYP) system. This system plays an important role in the disposition of a large number of drugs, including those used for migraine. This review examines the interactions between triptans-the most effective drugs for the therapy of migraine attacks-and drugs for migraine prophylactic treatment.
Ferrari
A
A
Department of Internal Medicine, Centre for the Study of Headache, Largo del Pozzo 71, 41100 Modena, Italy. annaf@unimore.it
Sternieri
E
E
Ferraris
E
E
Bertolini
A
A
D000700:Analgesics / Q000494:pharmacology* / Q000627:therapeutic use; D001711:Biotransformation / Q000187:drug effects; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects* / Q000378:metabolism*; D004347:Drug Interactions; D004790:Enzyme Induction / Q000187:drug effects; D006571:Heterocyclic Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D008881:Migraine Disorders / Q000503:physiopathology / Q000517:prevention & control*
D000700:Analgesics; D006571:Heterocyclic Compounds; D007527:Isoenzymes; D003577:Cytochrome P-450 Enzyme System